Management of menopausal syndrome in women with dyslipidemia.
10.3760/cma.j.cn112150-20221216-01208
- Author:
Yang Mei LI
1
;
Xun LEI
1
;
Li Li YU
2
Author Information
1. School of Public Health, Chongqing Medical University, Chongqing 400016, China.
2. Department of Obstetrics and Gynecology, the Third Affiliated Hospital of Chongqing Medical University, Chongqing 401120, China.
- Publication Type:Journal Article
- MeSH:
Female;
Humans;
Menopause;
Estrogen Replacement Therapy;
Cardiovascular Diseases/epidemiology*;
Estrogens/pharmacology*;
Dyslipidemias/drug therapy*
- From:
Chinese Journal of Preventive Medicine
2023;57(11):1908-1914
- CountryChina
- Language:Chinese
-
Abstract:
The prevalence of dyslipidemia is increased in postmenopausal women due to dysregulation of lipid metabolism and deficiency of estrogen levels. At the same time, some postmenopausal women also have menopausal syndromes such as vasomotor symptoms, physical physiology, mental psychology, and urogenital tract atrophy. Menopausal hormone therapy is the most effective measure to alleviate menopausal syndrome. And initiating MHT in early menopause can reduce cardiovascular damage. However, menopausal hormone therapy can also bring the risk of thromboembolic diseases such as venous embolism, myocardial infarction and stroke. Different drug regimens have different effects on lipid metabolism. Women with menopausal syndrome should take individualized treatment plans for different types of dyslipidemia. Therefore, this article reviews the management and treatment of menopausal syndrome in women with dyslipidemia, so as to provide a reference for personalized management of dyslipidemia in postmenopausal women.
